Difference between revisions of "Birtamimab (NEOD-001)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
m |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==[[Light-chain (AL) amyloidosis]]== | ==[[Light-chain (AL) amyloidosis]]== | ||
| − | # Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. [https:// | + | # '''NEOD001-001:''' Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. [https://doi.org/10.1200/JCO.2015.63.6530 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5470113/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26858336/ PubMed] [https://clinicaltrials.gov/study/NCT01707264 NCT01707264] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' NEOD-001 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
[[Category:Anti-amyloid antibodies]] | [[Category:Anti-amyloid antibodies]] | ||
| − | [[Category:Light-chain (AL) amyloidosis medications]] | + | [[Category:Light-chain (AL) amyloidosis medications (investigational)]] |
[[Category:Halted drugs]] | [[Category:Halted drugs]] | ||
Latest revision as of 11:00, 6 July 2024
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, anti-amyloid monoclonal antibody NEOD001 specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.
Preliminary data
Light-chain (AL) amyloidosis
- NEOD001-001: Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. link to original article link to PMC article PubMed NCT01707264
Also known as
- Code name: NEOD-001